Pulmolite Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of nuclear medicine infrastructure, increased prevalence of pulmonary embolism diagnosis, clinical adoption of technetium-based imaging agents, growth in hospital-based imaging services, regulatory approvals for radiopharmaceuticals.

The growth in the forecast period can be attributed to advancements in nuclear imaging technologies, rising demand for precise pulmonary diagnostics, expansion of outpatient diagnostic centers, increasing investment in nuclear medicine facilities, growing emphasis on early and accurate respiratory diagnosis. Major trends in the forecast period include increasing use of radiopharmaceuticals in diagnostic imaging, rising demand for lung perfusion scans, expansion of nuclear medicine procedures, growing focus on early detection of pulmonary disorders, improved radiotracer formulation stability.

The growing prevalence of respiratory disorders is expected to drive the Pulmolite market. Respiratory disorders are conditions that affect the respiratory system, including the airways, lungs, and related structures. These disorders can result from factors such as smoking, infections, environmental pollutants, allergens, occupational hazards, and genetic predispositions. Pulmolite supports the treatment of respiratory disorders by enhancing oxygen delivery and optimizing lung function, improving the body’s ability to exchange gases effectively. For instance, in June 2024, according to the Australian Institute of Health and Welfare, around 8.5 million Australians, or 34% of the population, were estimated to have chronic respiratory conditions. This included 2.8 million people (11% of the population) with asthma and 638,000 people (2.5%) with chronic obstructive pulmonary disease (COPD). Therefore, the rising incidence of respiratory disorders is fueling the growth of the Pulmolite market.

Rising air pollution levels are expected to further propel the Pulmolite market. Air pollution refers to the presence of harmful substances, including chemicals, particles, and gases, in the atmosphere that can adversely affect human health, ecosystems, and climate. The increase in air pollution is driven by factors such as industrial activity, vehicle emissions, deforestation, and fossil fuel use. Pulmolite assists in assessing lung damage caused by air pollution through diagnostic imaging of pulmonary function and blood flow. For example, in August 2024, according to the US Environmental Protection Agency, approximately 66 million tons of pollutants were released into the US atmosphere in 2023. Therefore, rising air pollution is contributing to the growth of the Pulmolite market.

Increasing healthcare expenditure is also expected to support the Pulmolite market. Healthcare expenditure includes spending on medical goods and services, preventive care, and public health initiatives aimed at improving health outcomes. Rising expenditure is driven by factors such as aging populations, chronic diseases, advanced medical technologies, high drug costs, and increased demand for healthcare services. Higher healthcare spending supports Pulmolite by advancing organ preservation technologies and improving access to lung transplantation procedures. For instance, in May 2024, according to the UK Office for National Statistics, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% rise in 2022, while long-term health and social care expenditure grew 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving the Pulmolite market.

Major companies operating in the pulmolite market are Solariz Healthcare Pvt Ltd.

North America was the largest region in the pulmolite market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmolite market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmolite market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the pulmolite market by increasing costs of imported radioisotopes, imaging equipment components, shielding materials, and radiopharmaceutical production supplies. Hospitals and diagnostic imaging centers in North America and Europe are most affected due to dependence on cross-border isotope supply chains, while Asia-Pacific faces higher production and logistics costs. These tariffs are increasing procedural expenses and limiting supply flexibility. However, they are also encouraging regional radioisotope production, domestic manufacturing of imaging consumables, and improved supply chain resilience for nuclear medicine diagnostics.

The pulmolite market research report is one of a series of new reports that provides pulmolite market statistics, including pulmolite industry global market size, regional shares, competitors with a pulmolite market share, detailed pulmolite market segments, market trends and opportunities, and any further data you may need to thrive in the pulmolite industry. This pulmolite market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmolite is a radiopharmaceutical used in medical imaging, particularly lung perfusion scans, to evaluate blood flow in the lungs. It contains technetium-99m-labeled particles that are injected into the bloodstream and accumulate in the lungs, aiding in the diagnosis of conditions like pulmonary embolism and assessing lung function before surgery.

The primary indications for Pulmolite include respiratory conditions, allergies, cough relief, and cold symptoms. Respiratory conditions involve diseases affecting the lungs and airways, and Pulmolite helps improve oxygenation and support lung function in these patients. It is distributed through direct sales, retail pharmacies, e-commerce platforms, and wholesalers, and is used by hospitals, clinics, ambulatory care centers, and homecare settings.

The pulmolite market consists of sales of acebrophyline and acetylcysteine tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.